Flightpath Biosciences, Inc., a clinical stage biotechnology company focused on the development of precision therapeutics targeting bacterial ...

Chinese biotech Brii Biosciences (HKEX: 2137) has licensed its experimental antibiotic BRII-693 to domestic pharma business ...

Basilea already secured $29 million to develop its antifungals fosmanogepix and BAL2062, and the Swiss company announced this morning that it has confirmed it will also receive its next tranche of $39 ...

Only one antibiotic – Sulbactam-durlobactam (brand name: Xacduro) – was effective against CRAB. Approved by US regulators in ...

Scientists have used Artificial Intelligence to generate a ready-to-use biological protein that can kill antibiotic resistant ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma ...

Family offices made 60 direct investments in companies, ending three straight months of declining deal activity.

Doctors and scientists are hopeful that the non-antibiotic treatment could ultimately help millions of patients ...

Ajay Sood addresses India's AMR challenges, emphasizing the need for stronger enforcement and innovative solutions at C-CAMP ...

As the globe faces a rise in antibiotic-resistant bacteria—making traditional ... now better known for its applications in medicine and biotechnology. CRISPR systems in general act as "molecular ...

New drugs that target 'zombie' tuberculosis (TB) cells are now a step closer, thanks to a new study led by the University of ...

Australians progressing the work of a Nobel prize-winning chemist have developed a superbug-­destroying protein using ...